FDA's eMDR program will soon be mandatory
This article was originally published in The Silver Sheet
FDA is urging device manufacturers to begin using the agency's electronic Medical Device Reporting (eMDR) program in anticipation that they will be required to do so as early as next spring. Currently, the eMDR program - which aims to improve CDRH's ability to analyze adverse event reports so it can identify troubling patterns more efficiently - is voluntary ("The Silver Sheet" August 2007). However, that will change once the agency issues a final rule on the program early next year, Don St. Pierre, CDRH associate director for postmarket transformation, said Sept. 25 at the Regulatory Affairs Professionals Society (RAPS) annual conference in Boston. "You can do [electronic reporting] now or you can wait for it to be done to you," he said, noting that so far only 15 eMDRs have been filed with FDA, all by one company
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.